secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001193125-22-005117
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus reports record preliminary Q4/FY2021 product revenue, guides 2022 up 20-25%
--------------------------------------------------------------------------------

- Q4 2021 preliminary product revenue $39.9M, up 41% YoY from $28.2M.
- Full-year 2021 preliminary product revenue $130.9M, above guidance of $127-129M.
- 2022 product revenue guidance $157-164M, representing 20-25% growth vs. 2021.
- More than half of U.S. platelets now treated with INTERCEPT on a run-rate basis.
- Nationwide launch of INTERCEPT Fibrinogen Complex after first BLA approval for Gulf Coast blood center.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522005117/0001193125-22-005117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522005117/d286874d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-005117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer